Kiniksa Pharmaceuticals International, plc (KNSA)
(Delayed Data from NSDQ)
$35.77 USD
-0.79 (-2.16%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $35.74 -0.03 (-0.08%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth D Momentum B VGM
Fundamental Charts
About PE Ratio (TTM)
Kiniksa Pharmaceuticals International, plc has a trailing-twelve-months P/E of 914.00X compared to the Medical - Biomedical and Genetics industry's P/E of 18.66X.
Price to Earnings Ratio or P/E is price / earnings. It is the most commonly used metric for determining a company's value relative to its earnings. In this example, we are using the actual earnings (EPS) for the trailing twelve months (or TTM). A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its trailing twelve months earnings. In general, a lower number or multiple is usually considered better than a higher one.
KNSA 35.77 -0.79(-2.16%)
Will KNSA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KNSA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KNSA
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
KNSA: What are Zacks experts saying now?
Zacks Private Portfolio Services
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Other News for KNSA
Slingshot Bullish appears for KNSA after 1.46% move
Tracking Baker Brothers Portfolio - Q2 2025 Update
KNSA makes New 52 Week Closing High on September 12
Is KNSA positioned for a breakout? New 52 Week Closing High shows up after rising 2.15%
Is KNSA set to rally? New 52 Week High shows up after sliding 1.71%